Correlates of tobacco product cessation among youth and adults in the USA: findings from the PATH Study Waves 1-3 (2013-2016).


Journal

Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612

Informations de publication

Date de publication:
05 2020
Historique:
received: 28 06 2019
revised: 19 09 2019
accepted: 26 09 2019
entrez: 24 4 2020
pubmed: 24 4 2020
medline: 3 6 2021
Statut: ppublish

Résumé

To report on demographic and tobacco use correlates of cessation behaviours across tobacco products (cigarettes, electronic nicotine delivery systems (ENDS), cigars, hookah and smokeless tobacco) among the US population. Data were drawn from the first three waves (2013-2016) of the Population Assessment of Tobacco and Health Study, a nationally representative, longitudinal cohort study of US youth (ages 12-17) and adults (ages 18+) . Past 30-day (P30D) tobacco users at Wave 1 (W1) or Wave 2 (W2) were included (n=1374 youth; n=14 389 adults). Generalised estimating equations were used to evaluate the association between demographic and tobacco use characteristics at baseline, with cessation behaviours at follow-up (discontinuing use, attempting to quit, quitting), over two 1-year periods (W1-W2, W2-Wave 3). Among adult users of each type of tobacco product, frequency of use was negatively associated with discontinuing use. Among adult cigarette smokers, non-Hispanic white smokers, those with lower educational attainment and those with lower household income were less likely to discontinue cigarette use; ENDS use was positively associated with making quit attempts but was not associated with cigarette quitting among attempters; smokeless tobacco use was positively associated with quitting among attempters; tobacco dependence was negatively associated with quitting among attempters. Among youth cigarette smokers, tobacco dependence was negatively associated with making quit attempts. Demographic correlates of tobacco cessation behaviours underscore tobacco use disparities in the USA. Use of ENDS and use of smokeless tobacco products are positively associated with some adult cigarette cessation behaviours.

Identifiants

pubmed: 32321854
pii: tobaccocontrol-2019-055255
doi: 10.1136/tobaccocontrol-2019-055255
pmc: PMC7520817
mid: NIHMS1604100
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

s203-s215

Subventions

Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: WMC reports long-term stock holdings in General Electric Company, 3M Company, and Pfizer Incorporated, unrelated to this manuscript. No financial disclosures were reported by the other authors of this paper.

Références

BMJ. 2017 Jul 26;358:j3262
pubmed: 28747333
Tob Induc Dis. 2017 Mar 14;15:17
pubmed: 28316562
Prev Med. 2014 May;62:14-9
pubmed: 24440684
Am J Epidemiol. 2018 Nov 1;187(11):2397-2404
pubmed: 29955810
Tob Control. 2005 Dec;14(6):422-4
pubmed: 16319367
Tob Control. 2020 May;29(Suppl 3):s155-s162
pubmed: 32321849
Tob Control. 2006 Jun;15(3):210-4
pubmed: 16728752
MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):157-164
pubmed: 30763302
Tob Control. 2020 May;29(Suppl 3):s134-s138
pubmed: 32321846
Addict Behav. 2010 Oct;35(10):900-4
pubmed: 20584571
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
J Environ Public Health. 2012;2012:679134
pubmed: 22666279
Addiction. 2011 Dec;106(12):2110-21
pubmed: 21752135
Tob Control. 2019 Jan;28(1):50-59
pubmed: 29695458
Tob Control. 2020 May;29(Suppl 3):s139-s146
pubmed: 32321847
Tob Control. 2020 May;29(Suppl 3):s191-s202
pubmed: 32321853
Am J Public Health. 2014 Aug;104(8):1437-44
pubmed: 24922154
Lancet Respir Med. 2016 Feb;4(2):116-28
pubmed: 26776875
Tob Control. 2020 May;29(Suppl 3):s163-s169
pubmed: 32321850
Tob Control. 2006 Jun;15 Suppl 3:iii83-94
pubmed: 16754952
Nicotine Tob Res. 2016 Jan;18(1):41-7
pubmed: 25744953
Vital Health Stat 2. 1969 Jan;(31):1-24
pubmed: 5306564
MMWR Morb Mortal Wkly Rep. 2017 Jan 06;65(52):1457-1464
pubmed: 28056007
Addict Behav. 2018 Sep;84:69-74
pubmed: 29627636
Tob Control. 2020 May;29(Suppl 3):s216-s226
pubmed: 32321855
Nicotine Tob Res. 2015 Oct;17(10):1187-94
pubmed: 25896067
Tob Control. 2020 May;29(Suppl 3):s178-s190
pubmed: 32321852
Addict Behav. 2015 Dec;51:113-9
pubmed: 26253939
Nicotine Tob Res. 2010 Oct;12 Suppl:S20-33
pubmed: 20889477
MMWR Morb Mortal Wkly Rep. 2018 Nov 09;67(44):1225-1232
pubmed: 30408019
Nicotine Tob Res. 2016 May;18(5):715-9
pubmed: 26525063
Nicotine Tob Res. 2019 Sep 19;21(10):1331-1338
pubmed: 30304476
N Engl J Med. 2017 Jan 26;376(4):342-353
pubmed: 28121512
Tob Control. 2020 May;29(Suppl 3):s170-s177
pubmed: 32321851
Tob Control. 2020 May;29(Suppl 3):s147-s154
pubmed: 32321848
Drug Alcohol Depend. 2017 Sep 1;178:257-266
pubmed: 28675817

Auteurs

Karin A Kasza (KA)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA karin.kasza@roswellpark.org.

Kathryn C Edwards (KC)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Zhiqun Tang (Z)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Cassandra A Stanton (CA)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.
Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.

Eva Sharma (E)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Michael J Halenar (MJ)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Kristie A Taylor (KA)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA.

Elisabeth A Donaldson (EA)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Lynn C Hull (LC)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Maansi Bansal-Travers (M)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Jean Limpert (J)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Izabella Zandberg (I)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Lisa D Gardner (LD)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Hoda T Hammad (HT)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Nicolette Borek (N)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA.

Heather L Kimmel (HL)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.

Wilson M Compton (WM)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.

Andrew Hyland (A)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH